REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma

• Published in: ESMO open Vol. 9; no. 4; p. 102943
• Main Authors: Caccese, M., Desideri, I., Villani, V., Simonelli, M., Buglione, M., Chiesa, S., Franceschi, E., Gaviani, P., Stasi, I., Caserta, C., Brugnara, S., Lolli, I., Bennicelli, E., Bini, P., Cuccu, A.S., Scoccianti, S., Padovan, M., Gori, S., Bonetti, A., Giordano, P., Pellerino, A., Gregucci, F., Riva, N., Cinieri, S., Internò, V., Santoni, M., Pernice, G., Dealis, C., Stievano, L., Paiar, F., Magni, G., De Salvo, G.L., Zagonel, V., Lombardi, G.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-04-2024
• Subjects: glioblastoma; real-world; recurrent; REGOMA; regorafenib; real-world; glioblastoma; regorafenib; REGOMA; recurrent
• ISSN: 2059-7029; 2059-7029
• DOI: 10.1016/j.esmoop.2024.102943

In the randomized phase II REGOMA trial, regorafenib showed promising activity in patients with recurrent glioblastoma. We conducted a large, multicenter, prospective, observational study to confirm the REGOMA data in a real-world setting.
The major inclusion criteria were histologically confirmed diagnosis of glioblastoma according to the World Health Organization (WHO) 2016 classification and relapse after radiotherapy with concurrent/adjuvant temozolomide treatment, good performance status [Eastern Cooperative Oncology Group performance status (ECOG PS 0-1)] and good liver function. Regorafenib was administered at the standard dose of 160 mg/day for 3 weeks on/1 week off. Brain magnetic resonance imaging was carried out within 14 days before starting regorafenib and every 8-12 weeks. The primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS), objective response rate, disease control rate (DCR), safety and health-related quality of life. The Response Assessment in Neuro-Oncology (RANO) criteria were used for response evaluation and Common Terminology Criteria for Adverse Events (CTCAE) version 5 for assessment of adverse events (AEs).
From September 2020 to October 2022, 190 patients with recurrent glioblastoma were enrolled from 30 cancer centers in Italy: their median age was 58.5 years [interquartile range (IQR) 53-67 years], 68% were male and 85 (44.7%) were in optimal clinical condition (ECOG PS 0). The number of patients taking steroids at baseline was 113 (60%); the second surgery was carried out in 39 (20.5%). O6-methylguanine-DNA methyltransferase (MGMT) was methylated in 80 patients (50.3%) and 147 (92.4%) of the patients analyzed had isocitrate dehydrogenase (IDH) wild type. The median follow-up period was 20 months (IQR 15.6-25.5 months). The median OS was 7.9 months ([95% confidence interval (CI) 6.5-9.2 months] and the median PFS was 2.6 months (95% CI 2.3-2.9 months). Radiological response was partial response and stable disease in 13 (7.3%) and 26 (14.6%) patients, respectively, with a DCR of 21.9%. The median number of regorafenib cycles per patient was 3 (IQR 2.0-4.0). Grade 3-4 drug-related adverse events were reported in 22.6% of patients. A dose reduction due to AEs was required in 36% of patients. No deaths were considered as treatment-related AEs.
This large, real-world observational study showed similar OS with better tolerability of regorafenib in patients with relapsed glioblastoma compared with the REGOMA study.
•This is the largest prospective study to evaluate the activity and safety of regorafenib in the real-world setting.•In this study, the survival was very similar to the REGOMA trial with a better controlled toxicity profile.•Molecular predictors of regorafenib efficacy need to be investigated to provide more personalized treatment.